RET (L790F)

RET · Variant type: point · HGVS: p.L790F

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Regorafenib	100.0%	0.0%	95.99
2	Pralsetinib	100.0%	0.0%	93.43
3	Ponatinib	100.0%	0.0%	78.23
4	Selpercatinib	99.9%	0.1%	96.72
5	Nintedanib	99.8%	0.2%	90.23
6	Tivozanib	99.8%	0.2%	92.42
7	Alectinib	99.7%	0.3%	95.49
8	Fedratinib	99.4%	0.6%	96.21
9	Lenvatinib	98.8%	1.1%	97.74
10	Entrectinib	98.6%	1.4%	93.69
11	Alpelisib	98.5%	1.6%	97.22
12	Brigatinib	97.8%	2.2%	82.96
13	Vandetanib	97.2%	2.8%	95.74
14	Cabozantinib	96.7%	3.3%	92.73
15	Gilteritinib	96.6%	3.4%	88.97
16	Sorafenib	96.5%	3.5%	96.72
17	Avapritinib	95.0%	5.0%	97.73
18	Tenalisib	95.0%	5.0%	97.98
19	Axitinib	94.3%	5.7%	93.23
20	Fostamatinib	92.8%	7.2%	96.74
21	Erdafitinib	90.3%	9.7%	95.71
22	Canertinib	89.8%	10.2%	96.49
23	Pazopanib	89.7%	10.3%	97.49
24	Futibatinib	89.6%	10.4%	98.48
25	Sunitinib	88.8%	11.2%	91.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Regorafenib	100.0%	98.7%	+1.3%
Pralsetinib	100.0%	100.0%	-0.0%
Ponatinib	100.0%	100.0%	-0.0%
Selpercatinib	99.9%	100.0%	-0.1%
Nintedanib	99.8%	100.0%	-0.2%
Tivozanib	99.8%	99.7%	+0.1%
Alectinib	99.7%	97.8%	+1.9%
Fedratinib	99.4%	99.9%	-0.4%
Lenvatinib	98.8%	98.8%	+0.0%
Entrectinib	98.6%	99.6%	-1.0%
Alpelisib	98.5%	99.6%	-1.2%
Brigatinib	97.8%	94.9%	+3.0%
Vandetanib	97.2%	98.6%	-1.3%
Cabozantinib	96.7%	97.5%	-0.8%
Gilteritinib	96.6%	100.0%	-3.4%
Sorafenib	96.5%	94.0%	+2.6%
Avapritinib	95.0%	—	—
Tenalisib	95.0%	98.5%	-3.6%
Axitinib	94.3%	—	—
Fostamatinib	92.8%	—	—
Erdafitinib	90.3%	94.7%	-4.4%
Canertinib	89.8%	—	—
Pazopanib	89.7%	—	—
Futibatinib	89.6%	97.7%	-8.1%
Sunitinib	88.8%	97.2%	-8.4%

Cancer	Organ	Source
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.7ms